Tissue-based gene expression testing in localized prostate cancer
Sivanesan N, Diaz G, Sprenkle P. Tissue-based gene expression testing in localized prostate cancer. Current Opinion In Urology 2025, 35: 432-438. PMID: 40314067, DOI: 10.1097/mou.0000000000001289.Peer-Reviewed Original ResearchConceptsLocalized prostate cancerTissue-based genomic testingProstate cancerRisk stratificationGenomic testingManagement of localized prostate cancerProstate cancer risk stratificationIdentified high-risk patientsClinically significant cancerProstate cancer outcomesImpact of genomic testingHigh-risk patientsAssess tumor aggressivenessLow-risk casesGenomic assaysGene expression testsTreatment decision-makingPSA levelsGleason scoreSignificant cancerOncotype DXTumor aggressivenessTherapeutic choiceReduce overtreatmentProspective studyAdvancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer
Smani S, DuBois J, Zhao K, Sutherland R, Rahman S, Humphrey P, Hesse D, Tan W, Martin D, Lokeshwar S, Ghali F. Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer. Current Oncology Reports 2025, 27: 236-246. PMID: 39976835, DOI: 10.1007/s11912-025-01645-7.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerInvasive bladder cancerBladder cancerRisk stratificationBCG-unresponsive NMIBCEarly radical cystectomyTERT promoter mutationsHigh-risk casesLong-term outcomesNadofaragene firadenovecIntravesical therapyTransurethral resectionRadical cystectomyTreatment paradigmStratified careReduce overtreatmentProgression riskIntegration of biomarkersPromoter mutationsClinical trialsTherapeutic strategiesReviewThis reviewPersonalized treatmentAdverse effectsClinical care
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply